Holen Sie sich die Stockscreener-App
7.78
6.27%
-0.52
Handel nachbörslich:
7.90
0.12
+1.54%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
Transcript : Capricor Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders - Morningstar
Applying big data sentiment scoring on Capricor Therapeutics Inc.Swing Trade & Weekly Watchlist for Hot Stocks - Newser
Published on: 2025-08-14 06:24:14 - Newser
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Capricor - GlobeNewswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces That Capricor Therapeutics, Inc. Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
Best data tools to analyze Capricor Therapeutics Inc. stockWeekly Trend Report & AI Driven Stock Price Forecasts - Newser
What does recent volatility data suggest for Capricor Therapeutics Inc.Weekly Gains Report & Free Community Consensus Stock Picks - Newser
Lawsuit Alert: Investors who lost money with shares of Capricor - openPR.com
2025-08-12 | CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit | NDAQ:CAPR | Press Release - Stockhouse
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP - GlobeNewswire
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics - FinancialContent
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
Capricor: Q2 Earnings Snapshot - Norwalk Hour
Levi & Korsinsky Reminds Capricor Therapeutics, Inc. - GlobeNewswire
Capricor Therapeutics Inc (CAPR) Q2 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Capricor Therapeutics: Q2 2025 Financial and Strategic Update - TipRanks
Capricor Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Earnings call transcript: Capricor Therapeutics Q2 2025 sees widened loss, stock dips - Investing.com
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
A mild market reaction for companies on Prasad’s return - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
Vinay Prasad’s Return to FDA Sends Biotech Shares Tumbling - Bloomberg.com
Investors in Capricor Therapeutics, Inc. Should Contact The Gross Law Firm Before September 15, 2025 to Discuss Your RightsCAPR - MarketScreener
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Zurcher Kantonalbank Zurich Cantonalbank Purchases 3,162 Shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Defense World
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor - GlobeNewswire
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure - Bluefield Daily Telegraph
Custom watchlist performance reports with Capricor Therapeutics Inc.Monthly Trade Result and Signal Summary - Newser
Analyzing drawdowns of Capricor Therapeutics Inc. with statistical toolsTrade Safety Matrix for Conservative Traders - Newser
What earnings revisions data tells us about Capricor Therapeutics Inc.Value Investing Summary and Earnings Outlook - Newser
Why Capricor Therapeutics Inc. is moving todayVolume Spike Detection for Early Breakouts - Newser
Class Action Filed Against Capricor Therapeutics, Inc. - GlobeNewswire
Capricor stock rises on FDA meeting for rejected drug (CAPR) - Seeking Alpha
Duchenne Muscular Dystrophy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sarepta Therapeutics, Santhera Pharma, ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics - Barchart.com
Capricor schedules FDA meeting on Duchenne therapy, delays earnings By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA | CAPR Stock News - GuruFocus
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for InvestorsContact Levi & Korsinsky - PR Newswire
Capricor Therapeutics Schedules FDA Meeting to Discuss Deramiocel BLA for Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA - GlobeNewswire
Capricor's DMD Treatment Reaches Critical FDA Milestone: Type A Meeting to Discuss BLA Path - Stock Titan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts - Defense World
Institutional scanner results for Capricor Therapeutics Inc.Risk Aware Swing Trade Analysis Insights - Newser
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):